Retrophin Inc. (RTRX) Stock Price Down 2.6%
Retrophin Inc. (NASDAQ:RTRX) shares traded down 2.6% during trading on Monday . The company traded as low as $23.59 and last traded at $23.61, with a volume of 360,350 shares changing hands. The stock had previously closed at $24.25.
A number of research analysts have recently commented on the company. JMP Securities reiterated a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. BMO Capital Markets reiterated a “buy” rating on shares of Retrophin in a research report on Monday, June 20th. Leerink Swann increased their target price on Retrophin from $27.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, September 7th. Finally, Zacks Investment Research upgraded Retrophin from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Thursday, July 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Retrophin presently has a consensus rating of “Buy” and a consensus price target of $27.60.
The company has a market cap of $853.63 million, a P/E ratio of 9.44 and a beta of 1.11. The firm’s 50 day moving average is $17.97 and its 200-day moving average is $16.53.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/retrophin-inc-rtrx-stock-price-down-2-6.html
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.30. Retrophin had a negative return on equity of 0.52% and a net margin of 83.57%. The company had revenue of $33.30 million for the quarter, compared to the consensus estimate of $32.73 million. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. Equities research analysts forecast that Retrophin Inc. will post $0.09 earnings per share for the current fiscal year.
In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $16.24, for a total transaction of $142,100.00. Following the sale, the executive vice president now owns 158,334 shares in the company, valued at approximately $2,571,344.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.41% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GW&K Investment Management LLC boosted its position in Retrophin by 88.3% in the first quarter. GW&K Investment Management LLC now owns 85,522 shares of the biopharmaceutical company’s stock valued at $1,168,000 after buying an additional 40,097 shares in the last quarter. Teachers Advisors Inc. boosted its position in Retrophin by 14.3% in the first quarter. Teachers Advisors Inc. now owns 231,492 shares of the biopharmaceutical company’s stock valued at $3,162,000 after buying an additional 28,956 shares in the last quarter. BlackRock Group LTD boosted its position in Retrophin by 54.8% in the first quarter. BlackRock Group LTD now owns 14,394 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 5,093 shares in the last quarter. BlackRock Fund Advisors boosted its position in Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock valued at $17,799,000 after buying an additional 22,903 shares in the last quarter. Finally, Spark Investment Management LLC boosted its position in Retrophin by 64.2% in the first quarter. Spark Investment Management LLC now owns 393,300 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 153,800 shares in the last quarter.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Receive News & Ratings for Retrophin Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Retrophin Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.